Hutchison Medical's introduction of anti-tumor drug tazemetostat tablets for more than 300 million US dollars applies for clinical application in China

On December 8, the latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China showed that a clinical trial application for tazemetostat hydrobromide tablets jointly submitted by Hutchison Medicine and Epizyme was accepted

Screenshot source: CDE official website

Public information shows that tazemetostat is a "first-in-class" EZH2 methyltransferase inhibitor developed by Epizyme.

As an EZH2 inhibitor, tazemetostat can inhibit the methylation of histone H3 lysine 27 by inhibiting EZH2, restore the expression of tumor suppressor genes, allow B cells to continue to differentiate or produce apoptosis, thereby controlling tumor growth

Prior to this (August this year), Hutchison Medicine and Epizyme reached a cooperation and obtained the development and commercialization rights of tazemetostat in Greater China (including Mainland China, Hong Kong, Macau and Taiwan)